Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs Lyfe Rx

GoodRx
Graded #122

Higher grade

vs+11.299999999999997
Lyfe Rx
Graded #375

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 58.3/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +30
80
50
Dose & formulationGoodRx +6
70
64
Clinical oversightGoodRx +2
69
67
Labs & monitoringLyfe Rx +1
51
52
FulfillmentGoodRx +19
81
62
Contract termsEven
55
55
GoodRx · left barLyfe Rx · right bar

The numbers

MetricGoodRxLyfe Rx
WeighScore69.6/10058.3/100
GradeCC
Scorecard rank#122#375
SemaglutideNot disclosed$225/mo (compounded)
Tirzepatide$299/mo (brand Zepbound)$299/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
GoodRx

Graded #122 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
Lyfe Rx

Graded #375 · C

Strengths

  • Both compounded semaglutide and tirzepatide available
  • Delivery to all 50 states with 1–3 day pharmacy turnaround

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Also sells non-prescription supplements ('Tirzepatide Weight Loss Supplement', 'Lipo Burn')
  • Shopify-based e-commerce storefront — less clinical infrastructure
  • FDA issued this company a warning letter dated 9 September 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard